Louise Mehrotra - VP, IR: Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson and it is my pleasure this morning to review our business results for the Fourth Quarter and Full Year of 2013.
Joining me on the podium today are Alex Gorsky, Chairman of the Board and Chief Executive Officer and Dominic Caruso, Vice President, Finance and Chief Financial Officer.
A few logistics before we get into the details. This review is being made available to a broader audience via a webcast accessible through the Investor Relations section of the Johnson & Johnson website.
I'll begin by briefly reviewing highlights of the fourth quarter and full year 2013 for the Corporation and highlights for our three business segments.
Following my remarks, Alex will comment on the 2013 results and provide a strategic outlook for the company. Dominic will then provide some additional commentary on the financial results and guidance for 2014. We will then open the meeting to your questions.
We expect the meeting to conclude at approximately 10.15. Included with the press release that was issued earlier this morning is a schedule of sales for key products and/or businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website, as is the press release. Also please note, the presentation to the Company's today's remarks is available on our website.
Before I get into the results, let me remind you that some of the statements made during this review may be considered forward-looking statements. The 10-K for the fiscal year 2012 identifies certain factors that could cause the Company's actual results to differ materially from those projected in any forward-looking statements made today. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments. The 10-K is available through the Company and online.
During the review, non-GAAP financial measures are used to provide information pertinent to ongoing business performance. These non-GAAP financial measures should not be considered replacements for GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the press release and on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.
A number of the compounds and products discussed today are being developed in collaboration with strategic partners or license from other companies. This slide acknowledges those relationships.
Now, I would like to review our results for the fourth quarter of 2013. If you would refer to your copy of the press release, let's begin with the schedule titled, Supplementary Sales Data by Geographic Area. Worldwide sales to customers were $18.4 billion for the fourth quarter of 2013, up 4.5% as compared to the fourth quarter of 2012. On an operational basis, sales were up 6.3% and currency had a negative impact of 1.8%.
In the U.S. sales were up 7.4% and regions outside the U.S., our operational growth was 5.6% while the effect of current exchange rates negatively impacted our reported results by 3.2%. Asian-Pacific/African region grew 7% operationally. Both Europe and the Western Hemisphere excluding U.S. grew by 4.8% operationally. The success of new product launches made strong contributions to the results in all regions.